Evidence map›Paper›PMID 39196448›Full record

ArticleEJNMMI research2024

Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.

Sebastian Martin, Lennard Wendlinger, Béatrice Zitti, Mehdi Hicham, Viktoriia Postupalenko, Léo Marx, Greta Giordano-Attianese, Elisabetta Cribioli, Melita Irving, Alexandra Litvinenko and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sebastian MartinTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland.
Lennard WendlingerTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland.
Béatrice ZittiAGORA, Pôle de recherche sur le cancer, Lausanne, 1011, Switzerland.
Mehdi HichamAGORA, Pôle de recherche sur le cancer, Lausanne, 1011, Switzerland.
Viktoriia PostupalenkoDebiopharm Research & Manufacturing SA, Campus "après-demain", Rue du Levant 146, Martigny, 1920, Switzerland.
Léo MarxDebiopharm Research & Manufacturing SA, Campus "après-demain", Rue du Levant 146, Martigny, 1920, Switzerland.
Greta Giordano-AttianeseLudwig Institute for Cancer Research, University of Lausanne, Epalinges, 1066, Switzerland.
Elisabetta CribioliLudwig Institute for Cancer Research, University of Lausanne, Epalinges, 1066, Switzerland.
Melita IrvingLudwig Institute for Cancer Research, University of Lausanne, Epalinges, 1066, Switzerland.
Alexandra LitvinenkoTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland.
Radmila FaizovaTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland.
David ViertlTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland.
Margret SchotteliusTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland. margret.schottelius@chuv.ch.ORCID http://orcid.org/0000-0002-1928-6913

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCXCR3 is expressed on activated T cells and plays a crucial role in T-cell recruitment to the tumor microenvironment (TME) during cell-based and immune checkpoint inhibitor (ICI) immunotherapy. This study utilized a PROCEDURES: CXCR3

resultsFlow cytometry analysis at baseline confirmed the presence of CXCR3 + T-cells in MC38 tumors, which was significantly increased at day five after ICI (treated 33.8 ± 17.4 vs. control 8.8 ± 6.2 CD3

conclusionsThis study demonstrates the feasibility of in vivo imaging of CXCR3 upregulation under immunotherapy using antibodies. However, high molar activities and low antibody doses are essential for sensitive detection in lymph nodes and spleen. Detecting therapy-induced changes in CXCR3

Indexed as

Chemokine receptorCXCR3ImmunotherapyT cell activation imaging

Identifiers

PMID39196448
PMCPMC11358572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.